These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 16764342)

  • 21. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis.
    Waubant E; Gee L; Miller K; Stabler G; Goodkin D
    J Interferon Cytokine Res; 2001 Mar; 21(3):181-5. PubMed ID: 11331041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
    Castellazzi M; Contini C; Tamborino C; Fasolo F; Roversi G; Seraceni S; Rizzo R; Baldi E; Tola MR; Bellini T; Granieri E; Fainardi E
    J Neuroinflammation; 2014 Nov; 11():188. PubMed ID: 25391491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
    Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
    Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis.
    Contini C; Cultrera R; Seraceni S; Castellazzi M; Granieri E; Fainardi E
    Mult Scler; 2004 Aug; 10(4):360-9. PubMed ID: 15327030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in subacute sclerosing panencephalitis.
    Ichiyama T; Matsushige T; Siba P; Suarkia D; Takasu T; Miki K; Furukawa S
    J Infect; 2008 May; 56(5):376-80. PubMed ID: 18395263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results.
    Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E
    J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation.
    Piccio L; Buonsanti C; Cella M; Tassi I; Schmidt RE; Fenoglio C; Rinker J; Naismith RT; Panina-Bordignon P; Passini N; Galimberti D; Scarpini E; Colonna M; Cross AH
    Brain; 2008 Nov; 131(Pt 11):3081-91. PubMed ID: 18790823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis.
    Palus M; Zampachová E; Elsterová J; Růžek D
    J Infect; 2014 Feb; 68(2):165-9. PubMed ID: 24091083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
    Nazdik MK; Taheri M; Sajjadi E; Arsang-Jang S; Koohpar ZK; Inoko H; Sayad A
    Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms.
    Fainardi E; Castellazzi M; Casetta I; Cultrera R; Vaghi L; Granieri E; Contini C
    J Neurol Sci; 2004 Feb; 217(2):181-8. PubMed ID: 14706222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
    Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
    J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
    J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules.
    Fainardi E; Granieri E; Tola MR; Melchiorri L; Vaghi L; Rizzo R; Castellazzi M; Ceruti S; Paolino E; Baricordi OR
    J Neuroimmunol; 2002 Dec; 133(1-2):151-9. PubMed ID: 12446018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis.
    Beuche W; Yushchenko M; Mäder M; Maliszewska M; Felgenhauer K; Weber F
    Neuroreport; 2000 Nov; 11(16):3419-22. PubMed ID: 11095490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.